A Phase 3 interventional study of Tranexamic Acid and Oxytocin in Post Partum Hemorrhage, sponsored by University of Zimbabwe. Completed at 2 sites in Zimbabwe. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-01.
Sponsored by University of Zimbabwe · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one is the 11th largest by enrollment, is one of 11 that started in 2018, is one of 16 in phase 3, and was the 20th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:
Wolfson Medical Center · Sites in Israel
Ages 18–51 · Women only · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–50 · Women only
Aligarh Muslim University · Sites in India
Ages 18–45 · Women only
London School of Hygiene and Tropical Medicine · Sites in Tanzania
Ages 18+ · Women only
Inova Health Care Services · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 18 · Phase 4 11
First in 2009; this study’s year is marked. 11 started in 2018.
This study's enrollment of 506 is above the median of 146 across 361 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 198 across the 50 interventional studies. Of the 35 that completed or were terminated, 7 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 50 has an industry lead sponsor. The 10 most frequent:
University of Zimbabwe is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
University of Zimbabwe has 2 studies filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
4 of the studies testing Tranexamic Acid in Postpartum Hemorrhage that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04304625Phase 3University Hospital, BordeauxTRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA | 2027-06 |
| NCT05562609Phase 3London School of Hygiene and Tropical MedicineTranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk | 2027-09 |
| NCT06754371RenJi HospitalProphylactic Tranexamic Acid Reduces Postpartum Hemorrhage | 2027-01 |
| NCT05370820Inova Health Care ServicesPrevention of Postpartum Hemorrhage With Tranexamic Acid | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background Postpartum haemorrhage (PPH) is a major cause of maternal mortality worldwide accounting for 25% of maternal deaths. In Zimbabwe PPH is the second most common cause of death. Tranexamic acid (TXA) is widely used to reduce blood loss in elective surgery, bleeding trauma patients, and menorrhagia.
The investigators seek to determine the efficacy of TXA in reducing PPH during and after elective caesarean section.
Methods and Design The investigators intend to perform an open label randomized control study of 1,162 women who are undergoing elective caesarean section. The participants will be randomly selected to receive an intravenous infusion of TXA 10 minutes prior to skin incision or not to receive the intervention. Prophylactic oxytocin will be administered to all the women.
The primary outcome will be incidence of PPH defined by blood loss equal to or more than 1,000ml calculated by determining the difference in haematocrit values taken prior to and 48 hours after caesarean section.
Discussion In addition to prophylactic uterotonic administration, TXA is a complementary component acting on the haemostatic process that can be used in the third stage of labour to prevent PPH. It is a promising intervention that is cheap, easy to administer and would be easy to add to routine delivery protocols in hospitals. It would also help to conserve precious resources by reducing the need for blood products, and expensive surgical interventions to manage PPH.
This large adequately powered randomized study seeks to determine the efficacy of TXA to validate its routine use at caesarean section to prevent PPH.
RESEARCH QUESTION Does intravenous Tranexamic Acid (TXA) 10mg/kg plus Oxytocin 5 International Units (IU) result in a lower incidence of primary postpartum haemorrhage compared to Oxytocin alone after elective caesarean section.
RATIONALE FOR THE RESEARCH Postpartum haemorrhage (PPH) is a major cause of maternal mortality worldwide accounting for 25% of maternal deaths. In Zimbabwe, PPH is the second most common cause of death. Tranexamic acid (TXA) is widely used to reduce blood loss in elective surgery, bleeding trauma patients, and menorrhagia.
In addition to prophylactic uterotonic administration, TXA is a complementary component acting on the haemostatic process that can be used in the third stage of labour to prevent PPH. It is a promising intervention that is cheap, easy to administer and would be easy to add to routine delivery protocols in hospitals. It would also help to conserve precious resources by reducing the need for blood products, and expensive surgical interventions to manage PPH.
The investigators seek to determine the efficacy of TXA in reducing PPH during and after elective caesarean section.
RESEARCH OBJECTIVES
To assess the potential adverse effects of TXA given 10 minutes prior to elective caesarean section Primary Outcome
Target Population Women undergoing elective caesarean sections at Harare and Parirenyatwa Hospitals based on set inclusion and exclusion criteria Inclusion criteria Pregnant woman with signed informed consent, who understand English and/or Shona, at estimated gestational age of 38 weeks or older, requiring Elective Caesarean Section, with a live intrauterine fetus.
Exclusion criteria Placental Abruption, emergency caesarean section, current or previous history of significant disease including heart disease, liver, renal disorders; known coagulopathy or history of deep venous thrombosis and/or pulmonary embolism, or arterial thrombosis (angina pectoris, myocardial infarction, stroke); history of epilepsy or seizures; autoimmune disease; sickle cell disease; severe haemorrhagic disease; intrauterine fetal demise; eclampsia/HELLP syndrome; administration of anticoagulants - clexane or antiplatelet agents in the week prior to delivery.
Sample Size A total sample size of 1,162 (581 per group) was calculated assuming a proportion of 2.1% PPH in the experimental group and 5.8% in the control group at 95% confidence interval and 90% power using Fleiss formula.
Subjects' state of physical health Healthy Intervention Participants receive either 10mg/kg of TXA 10 minutes prior to elective caesarean section with prophylactic oxytocin administration after delivery of the baby, versus prophylactic oxytocin alone after delivery of the baby.
Assessment Questionnaire (attached). Vital signs (heart rate, blood pressure, respiratory rate) noted before surgery, immediately after placental delivery, and 1 to 2 hours after birth Full blood count (FBC), Urea \& electrolytes (u\&e) and liver function tests (LFTs) performed a day before delivery (routinely performed) U\&e, LFTs and FBC assessed 48 hours after delivery. Estimated blood loss (EBL) using the difference in hematocrit values taken prior to and 48 hours after caesarean delivery.
The investigators will also note the standard EBL based on estimates made by the anaesthetist after assessment of patient's linen and abdominal swabs.
RISKS AND BENEFITS The common adverse effects include headaches (50.4 - 60.4%), backaches (20.7 - 31.4%), nasal sinus problem (25.4%), abdominal pain (12 - 19.8%), diarrhea (12.2%), fatigue (5.2%) and anaemia (5.6%).
The WOMAN Trial collaborators found that TXA actually reduces mortality due to bleeding in women with PPH with no adverse effects.
Tranexamic acid potentiates the blood clotting system and is used to treat and prevent bleeding. Use of TXA could potentially prevent PPH due to factors other than uterine atony, where uterotonics will not be effective.
COSTS AND COMPENSATION Study participants will not receive any compensation. The cost of TXA shall not be incurred by the study participants. They will bear their usual admission and caesarean section costs that they would otherwise have borne had they not participated in the study.
INFORMED CONSENT All subjects or legally authorized representatives for minors are expected to be give informed consent.
CONFIDENTIALITY ASSURANCES Information collected from the participants shall be confidential, will be assigned a code and no personal identifiers will be used. Information collected will be stored in a secure place only accessible to the researcher and assistants, as well as on a password-protected laptop computer. Consent forms will be kept for three years after the completion of the investigation unless stipulated otherwise by the Medical Research Council of Zimbabwe.
CONFLICTS OF INTERESTS The study is being carried out in partial fulfillment of the degree of Masters of Medicine in Obstetrics and Gynaecology. No other gains are to be obtained from carrying out the study.
COLLABORATIVE AGREEMENTS N/A INTENDED USE OF RESULTS The results of the study will be submitted to the College of Health Sciences as part of the requirements for completion of the degree of Masters of Medicine in Obstetrics and Gynaecology, and may be considered for publications to add to the current body of knowledge on the use of TXA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Live intrauterine fetus
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.
Drug: Tranexamic Acid · Drug: Oxytocin
Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby
Drug: Oxytocin
TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.
Also known as: TXA
5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
Also known as: Prophylactic oxytocin
Number of Participants With Postpartum Haemorrhage (PPH)
PPH based on Haematocrit calculation and PPH based on Haemoglobin calculation
Time frame: Up to 48 hours post-caesarean section
Estimated Blood Loss
Blood loss during caesarean section based on visual estimation and calculation.
Time frame: At caesarean section
Amount of Blood Transfused
Requirement by participant of blood transfusion
Time frame: At caesarean section up to 48 hours post-caesarean section
Number of Participants With Use of Additional Uterotonics
Number of participants who received additional uterotonics such as an oxytocin infusion or prostaglandin (misoprostol).
Time frame: At caesarean section up to 48 hours post-caesarean section
Number of Participants With Tranexamic Acid Side Effects
Number of participants with adverse effects related to tranexamic acid use
Time frame: From intravenous infusion of the drug up to 48 hours post-caesarean section
Number of Participants Requiring Emergency Surgery for PPH
Number of participants requiring emergency surgical procedures to manage any PPH that occurs
Time frame: At caesarean section up to 48 hours post-caesarean section
Number of Days of Participants' Hospital Stay
The number of days the participant stayed in hospital from the date of admission to date of discharge from hospital.
Time frame: From date of randomization until the day 2 post-caesarean section (date of discharge from hospital) or date of death whichever comes earlier
Neonatal Outcome - Weight
Neonatal birth weight in grams
Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
Neonatal Outcome - APGAR Score of the Neonates at 1 Minute and 5 Minutes After Delivery
APGAR (Appearance, Pulse, Grimace, Activity, Respiration) scores out of 10 at 1 minute and 5 minutes. A measure of the physical condition of a newborn infant. It is obtained by adding points (maximum score of 2, 1, or 0 as minimum score) for Appearance (0 - blue/pale, 1 - pink body, blue extremities, 2 - pink); Pulse (0 - absent heart rate, 1 - below 100 beats per minute, 2 - over 100 beats per minute), Grimace (Reflex irritability - 0 - floppy, 1 - minimal response to stimulation, 2- prompt response to stimulation), Activity (muscle tone: 0 - absent, 1 - Flexed arms and legs, 2 - active), Respiration ( 0 - absent, 1 - slow or irregular, 2 - vigorous cry). APGAR score at 1minute or 5 minute can be a minimum of of 0 (0+0+0+0+0) or maximum of 10 (2 for each parameter above).
Time frame: Scores at 1 minute from time of delivery and at 5 minutes after delivery
Neonatal Outcome - Number of Neonates Admitted to the Neonatal Unit
Number of neonates requiring admission to the neonatal unit from time of delivery at caesarean section
Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
Neonatal Outcome - Number of Neonates Diagnosed With Jaundice
Number of neonates with clinical jaundice (yellowing of the skin or whites of the eyes)
Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
Neonatal Outcome - Thromboembolic Event
Number of neonatal thromboembolic events
Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
Neonatal Outcome - Death
Neonatal death that occurs
Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
From 8 April 2018 to 31 December 2018, we recruited 506 eligible patients. The trial was conducted at two tertiary institutions that are affiliated to the University of Zimbabwe. These serve as referral centres for 12 local authority clinics located in Harare as well as district and provincial hospitals in the surrounding provinces: Harare Central Hospital i.e. Harare Maternity Hospital (HMH) and Parirenyatwa Group of Hospitals i.e. Mbuya Nehanda Maternity Hospital (MNMH).
| Milestone | Group A | Group B |
|---|---|---|
| Started | 253 | 253 |
| Completed | 224 | 227 |
| Not completed | 29 | 26 |
| Withdrew: Lost to follow-up | 7 | 8 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Protocol violation | 4 | 1 |
| Withdrew: Had a vaginal delivery prior to caesarean delivery | 9 | 11 |
| Withdrew: Had emergency caesarean delivery prior to elective caesarean delivery | 7 | 6 |
PPH based on Haematocrit calculation and PPH based on Haemoglobin calculation
| Participants | Group A | Group B |
|---|---|---|
| PPH based on Haematocrit calculation | 48 | 54 |
| PPH based on Haemoglobin calculation | 56 | 71 |
Blood loss during caesarean section based on visual estimation and calculation.
| ml | Group A | Group B |
|---|---|---|
| Visually estimated blood loss | 483.73 ± 182.56 | 479.61 ± 139.49 |
| Haematocrit-based calculation of estimated blood loss | 650.06 ± 631.50 | 653.05 ± 796.03 |
| Haemoglobin-based calculation of estimated blood loss | 644.30 ± 692.27 | 707.68 ± 948.01 |
Requirement by participant of blood transfusion
| units of blood given | Group A | Group B |
|---|---|---|
| Amount of Blood Transfused | 1.5 (1 to 2) | 2.5 (2 to 3) |
Number of participants who received additional uterotonics such as an oxytocin infusion or prostaglandin (misoprostol).
| Participants | Group A | Group B |
|---|---|---|
| Number of Participants With Use of Additional Uterotonics | 38 | 32 |
Number of participants with adverse effects related to tranexamic acid use
| Participants | Group A | Group B |
|---|---|---|
| Number of Participants With Tranexamic Acid Side Effects | 7 | 3 |
Number of participants requiring emergency surgical procedures to manage any PPH that occurs
| Participants | Group A | Group B |
|---|---|---|
| Number of Participants Requiring Emergency Surgery for PPH | 0 | 2 |
The number of days the participant stayed in hospital from the date of admission to date of discharge from hospital.
| days | Group A | Group B |
|---|---|---|
| Number of Days of Participants' Hospital Stay | 5 (4 to 5) | 5 (4 to 5) |
Neonatal birth weight in grams
| grams | Group A | Group B |
|---|---|---|
| Neonatal Outcome - Weight | 3087.85 ± 523.98 | 3109.98 ± 513.13 |
APGAR (Appearance, Pulse, Grimace, Activity, Respiration) scores out of 10 at 1 minute and 5 minutes. A measure of the physical condition of a newborn infant. It is obtained by adding points (maximum score of 2, 1, or 0 as minimum score) for Appearance (0 - blue/pale, 1 - pink body, blue extremities, 2 - pink); Pulse (0 - absent heart rate, 1 - below 100 beats per minute, 2 - over 100 beats per minute), Grimace (Reflex irritability - 0 - floppy, 1 - minimal response to stimulation, 2- prompt response to stimulation), Activity (muscle tone: 0 - absent, 1 - Flexed arms and legs, 2 - active), Respiration ( 0 - absent, 1 - slow or irregular, 2 - vigorous cry). APGAR score at 1minute or 5 minute can be a minimum of of 0 (0+0+0+0+0) or maximum of 10 (2 for each parameter above).
| units on a scale up to 10 | Group A | Group B |
|---|---|---|
| Apgar score at 1 minute | 8 (8 to 9) | 9 (8 to 9) |
| Apgar score at 5 minutes | 9 (9 to 10) | 9 (9 to 10) |
Number of neonates requiring admission to the neonatal unit from time of delivery at caesarean section
| Participants | Group A | Group B |
|---|---|---|
| Neonatal Outcome - Number of Neonates Admitted to the Neonatal Unit | 33 | 23 |
Number of neonates with clinical jaundice (yellowing of the skin or whites of the eyes)
| Participants | Group A | Group B |
|---|---|---|
| Neonatal Outcome - Number of Neonates Diagnosed With Jaundice | 1 | 0 |
Number of neonatal thromboembolic events
| Participants | Group A | Group B |
|---|---|---|
| Neonatal Outcome - Thromboembolic Event | 0 | 0 |
Neonatal death that occurs
| Participants | Group A | Group B |
|---|---|---|
| Neonatal Outcome - Death | 1 | 1 |
Collected over Adverse event data was collected up to the time the patient and baby were discharged from hospital which on average is on the third day post-caesarean section.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A | 0/224 (0%) | 0/224 (0%) | 7/224 (3.1%) |
| Group B | 0/227 (0%) | 0/227 (0%) | 3/227 (1.3%) |
| Event | Group A | Group B |
|---|---|---|
| HypotensionCardiac disorders | 3/224 | 1/227 |
| NauseaGastrointestinal disorders | 2/224 | 0/227 |
| HeadacheNervous system disorders | 1/224 | 1/227 |
| VomitingGastrointestinal disorders | 1/224 | 1/227 |
| Age, Continuous(years) | Group A | Group B | Total |
|---|---|---|---|
| Mean | 29.5 ± 6.0 | 29.7 ± 6.5 | 29.6 ± 6.3 |
| Sex: Female, Male(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Female | 224 | 227 | 451 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Black African | 224 | 227 | 451 |
| Region of Enrollment(participants) | Group A | Group B | Total |
|---|---|---|---|
| Zimbabwe | 224 | 227 | 451 |
| Gestational age(Weeks) | Group A | Group B | Total |
|---|---|---|---|
| Median | 39 (38 to 40) | 39 (38 to 40) | 39 (38 to 40) |
| HIV status(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Positive | 27 | 35 | 62 |
| Negative | 186 | 187 | 373 |
| Unknown | 11 | 5 | 16 |
| Multiple pregnancy(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Count of participants | 6 | 6 | 12 |
| Placenta praevia(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Count of participants | 5 | 1 | 6 |
10 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — It is undecided whether the IPD will be made available to other researchers. Clearance is required first from ethical bodies and supervisors
Supporting information: Study protocol, Statistical analysis plan
Time frame: TBA
Access criteria: Communicate with researcher on chipo.gwanzura@gmail.com
Ran from Apr 2018 to primary completion in Dec 2018, 8 months.
Results were first posted in Apr 2022, 3 years 3 months after primary completion.
Of 20 phase 3 interventional studies under Postpartum Hemorrhage, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
University of Zimbabwe